dimethyl 2-[3-[(3R,3'R,4'S,6'R,8'S,8'aS)-8'-carbamoyl-6'-[2-(2-hydroxyethoxy)phenyl]-1',2-dioxo-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-5-yl]prop-2-ynyl]propanedioate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: dimethyl 2-[3-[(3R,3'R,4'S,6'R,8'S,8'aS)-8'-carbamoyl-6'-[2-(2-hydroxyethoxy)phenyl]-1',2-dioxo-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-5-yl]prop-2-ynyl]propanedioate
• 化学式: C₄₃H₃₉N₃O₁₀
• 分子量: 757.8
• InChiKey: VTQFIMAQORENEW-HTWKETGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  56
• 可旋转键数：
  13
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  184
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS
  申请人：Tsai Li-Huei

  公开号：US20130004517A1

  公开（公告）日：2013-01-03

  The invention relates to methods of treating neurological disorders in a subject, by activating a DISC 1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided.